EACH YEAR, there are about 500,000 patients who develop sepsis, which has a mortality rate of about 50% (1). More than half of the sepsis cases are derived from infection of Gram-negative bacteria. A variety of pharmacophysiological responses are derived from the host’s inflammatory response to endotoxin of these Gram-negative bacteria. The hyperinflammatory responses of the host are thought to be the cause of organ injury and death in patients with sepsis. These responses include the release of a large amount of pro-inflammatory cytokines, including but are not limiting to tumor necrosis factor-a (TNF-a), interleukin-1 (IL-1), IL-6, IL-8, platelet activating factor (PAF), eicosanoids, complement components, kinins, and other mediators. Production of these mediators cause systemic inflammatory response syndrome (SIRS), which could progress to hypotension, hypoperfusion, dysfunction of individual or multiple organ systems (2,3). The important role of proinflammatory cytokines in sepsis development has been demonstrated in many studies. One to 2 h after endotoxin administration, the production of TNF-a was highest in sera of mice, rats, chimpanzees, and humans (4–14). Depending on the species, the level reverts back to normal by 2–10 h. With a little delay of few hours, similar response curves are observed for IL-1, IL-6, and IL-8 after endotoxin administration in many of these studies. The consequence observed in the host is the active hyperdynamic response, which includes an increased cardiac output, tachycardia, decreased vascular resistance, lymphopenia, neutrophilia, organ injury, anorexia, inflammation, fever, chills, myalgia, headache, and other symptoms (15–22). Elevation of these proinflammatory cytokines is correlated with mortality in patients with sepsis in the intensive care unit in several of the above studies. On the basis of these observations, a number of clinical trials were done in blocking the activity of these cytokines. The administration was done either in the form of antibodies to a particular cytokine, such as TNF-a and IL-1, in the form of soluble receptors capable of binding and inactivating the cytokine of interest (23–31). None of these studies has been shown to be beneficial in clinical terms. Some of the major reasons include the fact that endotoxin instead of bacterial infection was used in many animal studies. Furthermore, blocking the activity or production of the active cytokines involved in the very inflammatory response to eliminate the invading pathogen effectively may be a mistake in designing a therapy for treating patients with sepsis. Therefore, new treatment approaches will be undoubtedly attractive for this clinical problem.